Between Dec. 23, 2024 and Jan. 3, 2025, eCommons staff will not be available to answer email and will not be able to provide DOIs until after Jan. 6. If you need a DOI for a dataset during this period, consider Dryad or OpenICPSR. If you need support submitting material before the winter break, please contact us by Thursday, Dec. 19 at noon. Thank you!
Library

eCommons

 

Transdermal Scopolamine Drug Delivery Systems for Motion Sickness

Simple item page
dc.contributor.authorFung, Gloria
dc.contributor.authorHo, Terence
dc.contributor.authorLee, Soyoon
dc.contributor.authorMunaretto, Joseph
dc.contributor.authorTsai, Christine
dc.date.accessioned2004-07-12T20:48:00Z
dc.date.available2004-07-12T20:48:00Z
dc.date.issued2003-07-12T20:48:00Z
dc.description.abstractTransdermal drug delivery systems are involved in the continuous administration of drug molecules from the surface of the skin into the circulatory system. Such systems have proved advantageous for delivery of certain drugs, such as scopolamine, nicotine, nitroglycerine, and estradiol. Compared with oral administration, transdermal drug delivery offers better uniformity of drug concentrations in plasma throughout their duration of use. Scopolamine is the active ingredient in motion sickness medication that targets the nerve fibers in the inner ear. The scopolamine patch is effective for about three days, longer than if administered orally which is effective for only several hours. One of the main restraints of this transdermal system is its absorption through the skin, especially through the stratum corneum, its outermost part. This study examines the rate of diffusion of transdermal scopolamine across the skin and into the systemic circulation. Our objective is to optimize the drug delivery by way of a scopolamine patch by minimizing absorption rates, while maintaining its advantage of a long-term effect. A comparative study of the effects in the presence of penetration enhancers were undertaken to show how steady state is approached at different rates. The model we used does offer certain limitations, as diffusivity values specific to human skin and scopolamine are not readily available.en_US
dc.format.extent265346 bytes
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/1813/141
dc.language.isoen_US
dc.relation.ispartofseries2003;11
dc.subjectTransdermal Scopolamine Drug Deliveryen_US
dc.subjectmotion sicknessen_US
dc.titleTransdermal Scopolamine Drug Delivery Systems for Motion Sicknessen_US
dc.typereporten_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Transdermal.pdf
Size:
259.13 KB
Format:
Adobe Portable Document Format
Download

Collections

BEE 4530 - 2003 Student Papers